Total-body and myocardial substrate oxidation in congestive heart failure
References (33)
- et al.
Plasma norepinephrine in congestive heart failure
Am J Cardiol
(1978) - et al.
Activity of the sympathetic nervous system and renin angiotensin system assessed by plasma hormone levels and their relationship to haemodynamic abnormalities in congestive heart failure
Am J Cardiol
(1982) - et al.
Heterogenous myocardial catecholamine concentrations in patients with congestive heart failure
Am J Cardiol
(1987) - et al.
Hormonal effects of norepinephrine on acute glucose disposal in humans: A minimal model analysis
Metabolism
(1988) - et al.
Insulin resistance and hyperinsulinemia in patients with congestive heart failure
Metabolism
(1991) - et al.
Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects
Metabolism
(1987) - et al.
Symptoms and tests of ventricular performance in the evolution of chronic heart failure
Am Heart J
(1986) The theoretical basis of indirect calorimetry: A review
Metabolism
(1988)- et al.
Evidence for peripheral impaired glucose handling in patients with connective tissues diseases
Metabolism
(1991) - et al.
Metabolic and cardiovascular benefits deriving from B-adrenergic blockade in chronic congestive heart failure
Am Heart J
(1992)
The glucose fatty acid cycle. Its role in insulin sensitivity and the metabolic disturbance of diabetes mellitus
Lancet
Mechanism of palmityl coenzyme A inhibition of liver glycogen synthase
J Biol Chem
Stimulation of gluconeogenesis by palmitic acid in rat hepatocytes. Evidence that this effect can be dissociated from the provision of reducing equivalent
Metabolism
Relationship in man between plasma free fatty acids and myocardial metabolism of carbohydrate substrates
Lancet
Plasma norepinephrine as guide to prognosis in patients with chronic congestive heart failure
N Engl J Med
The adrenergic nervous system in heart failure
N Engl J Med
Cited by (154)
Insulin resistance and metabolic flexibility as drivers of liver and cardiac disease in T2DM
2023, Diabetes Research and Clinical PracticeThe glycolytic pathway to heart failure
2023, Glycolysis: Tissue-Specific Metabolic Regulation in Physio-pathological ConditionsCardiac energy metabolism in heart failure
2023, Cardiovascular Endocrinology and Metabolism: Theory and Practice of Cardiometabolic MedicineIdentifying functional metabolic shifts in heart failure with the integration of omics data and a heart-specific, genome-scale model
2021, Cell ReportsCitation Excerpt :In the case of ketone body utilization, a recent metabolomics analysis suggests that changes in circulating levels of ketone bodies influence increased use in late-stage heart failure (Murashige et al., 2020). Although the role of fatty acids in late-stage heart failure remains controversial, with some studies measuring increased use (Paolisso et al., 1994; Taylor et al., 2001) whereas animal models measure no change (Zhabyeyev et al., 2013) or decreased use (Allard et al., 1994; Neubauer, 2007), the TIDEs analysis demonstrated no consistent change in gene expression for fatty acid oxidation in late-stage heart failure (Figures 5B and S3B). Together, this suggests that factors other than changes in transcription are driving the measured changes in metabolite uptake for ketone bodies, amino acids, and fatty acids in late-stage heart failure.
Role of mitochondrial quality surveillance in myocardial infarction: From bench to bedside
2021, Ageing Research ReviewsKetone metabolism in the failing heart
2020, Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids